Ocrelizumab as a breakthrogh in multiple sclerosis treatment
DOI:
https://doi.org/10.12775/JEHS.2021.11.05.005Keywords
ocrelizumab, multiple sclerosis, ppms, rrms, monoclonal antibodyAbstract
Multiple sclerosis is the most commonly occurring inflammatory disease of the nervous system. It is estimated that over 2 million people suffer from this disease. Currently SM is untreatable, one can only try to stop the progression of the disease or reduce severity of the symptoms.
There have been numerous studies on the effectiveness of other monoclonal antibodies in the treatment of multiple sclerosis. A drug that offers a chance for a breakthrough in the treatment of multiple sclerosis is ocrelizumab. It is a monoclonal antibody directed against B lymphocytes expressing the CD20 antigen.
Results of the studie confirm the efficacy of ocrelizumab in inhibiting ongoing nerve fiber degeneration and reducing the inflammation associated with it, as well as the near complete depletion of CD20+ B lymphocytes and partial depletion of CD20+ T lymphocytes. They also suggest that ocrelizumab is a safe and effective treatment for multiple sclerosis.
Studies conducted on the therapeutic efficacy of ocrelizumab show that its effect on disease progression is superior compared to some current drugs. Ocrelizumab also has a similar safety profile to the currently used interferon β-1a. An important feature of ocrelizumab is its efficacy in the treatment of the primary progressive form of MS, where significant therapeutic efficacy with other drugs has not been seen to date.
References
Reich D.S., Lucchinetti C.F., Calabresi P.A.: Multiple Sclerosis; N Engl J Med. 2018 Jan 11; 378(2): 169–180.
Browne P., Chandraratna D., Angood C., Tremlett H., Baker C., Taylor BV., Thompson AJ.: Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014 Sep 9;83(11):1022-4
Ascherio A.: Environmental factors in multiple sclerosis. Expert Rev Neurother. 2013 Dec;13(12 Suppl):3-9.
Greenfield AL, Hauser SL. B‐cell therapy for multiple sclerosis: entering an era. Ann Neurol. 2018 Jan;83(1):13-26.
Kamińska J, Koper O.M., Piechal K., Kemona H.: Stwardnienie rozsiane – etiopatogeneza i możliwości diagnostyczne. Postepy Hig Med Dosw (online), 2017; 71: 551-563
Lassmann H. Pathology and disease mechanisms in different stages of multiple sclerosis. JJ Neurol Sci. 2013 Oct 15;333(1-2):1-4.
Walczak A., Arkuszewski M., Adamczyk-Sowa M.: Rozszerzona Skala Niesprawności (EDSS, Expanded Disability Status Scale) — według J. Kurtzkego.
Kostiukow A., Malak R., Rostkowska E., Samborski W.: Wykorzystanie testów koordynacji ruchowej w diagnostyce wybranych jednostek chorobowych.
Reich D.S., Lucchinetti C.F., Calabresi P.A.: Multiple Sclerosis. N Engl J Med. 2018 Jan 11;378(2):169-180.
Losy J., Bartosik-Psujek H., Członkowska A., Kurowska K., Maciejek Z., Mirowska-Guzel D., Potemkowski A., Ryglewicz D., Stępień A.: Leczenie stwardnienia rozsianego Zalecenia Polskiego Towarzystwa Neurologicznego; ViaMedica
Alimohamadi S., Vollmer B., Nair K., Sillau S., Corboy J., Vollmer T., Alvarez E.: Ocrelizumab Safety and Effectiveness in the One Year Treatment of Multiple Sclerosis Compared to Other Disease Modifying Therapies (P3.2-053)
Sarnecki K., Stadnik M., Krysiak R., Okopień B.: Przeciwciała monoklonalne w leczeniu modyfikującym przebieg postaci remitująco-rzutowej stwardnienia rozsianego – stan obecny a perspektywy na przyszłość; Aktualn Neurol 2012, 12 (1), p. 30-39
Montalban X., Hemmer B., Rammohan K. i wsp. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis — results of the placebo-controlled, double-blind, phase III ORATORIO study. 31th Congress of The European Committee For Treatment and Research in Multiple Sclerosis. 7–10 październik, 2015. Barcelona, Hiszpania.
European Medicne Agency: Streszczenie EPAR dla ogółu społeczeństwa
McCool R., Wilson K., Arber M., Fleetwood K., Toupin S., Thom H., Bennet I., Edward S.: Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis; Multiple Sclerosis and Related Disorders; Volume 29, April 2019, Pages 55-61
Alimohamadi S., Vollmer B., Nair K., Sillau S., Corboy J., Vollmer T., Alvarez E.: Ocrelizumab Safety and Effectiveness in the One Year Treatment of Multiple Sclerosis Compared to Other Disease Modifying Therapies (P3.2-053)
Barkhof F., Kappos L., Wolinsky J.S., Li D.K.B., Bar-Or A., Hartung H., Belachew S., Han J., Julian L., Sauter A., Napieralski J., Koendgen H., Hauser S.L.: Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
Gingele S., Jacobus T.L., Konen F.F., Hümmert M.W., Sühs K., Schwenkenbecher P., Ahlbrecht J., Möhn N., Müschen N., Bönig L., Alvermann S., Schmidt R.E. Stangel M., Jacobs R., Skripuletz T.: Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
Cross A., Bennett J., von Büdingen H.C., Carruthers R., Edwards K., Fallis R., Fiore D., Gelfand J., Giacomini P., Greenberg B., Hafler D., Harp C., Assman B., Herman A., Ionete C., Kaunzner U., Lock C., Ma X., Musch B., Pardo G., Piehl F., Weber M., Ziemssen T., Bar-Or A.: Ocrelizumab treatment reduced levels of neurofilament light chain and numbers of B cells in the cerebrospinal fluid of patients with relapsing multiple sclerosis in the OBOE study (S56.008)
Stephen L. Hauser, M.D., Amit Bar-Or, M.D., Giancarlo Comi, M.D., Gavin Giovannoni, M.D. : Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017; 376:221-234
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 744
Number of citations: 0
